Literature DB >> 15689220

Actinic granuloma successfully treated with acitretin.

C Stefanaki1, A Panagiotopoulos, P Kostakis, K Stefanaki, A Petridis.   

Abstract

Actinic granuloma is a rare skin disorder that develops in an area of actinic elastosis. The pathogenesis of the disease is obscure but the most accepted hypothesis implicates the solar radiation as the triggering factor. Typically the disease presents in middle-aged individuals with significant past sun-exposure and involves mainly the sun-exposed skin. It manifests as asymptomatic annular patches with elevated borders and central atrophy and shows little tendency to regression. Several treatments have been tried with variable success. We present a 74-year-old male who consulted our department for annular atrophic plaques involving his forehead and nose, present for 8 months and insidiously spreading but otherwise asymptomatic. A biopsy confirmed the clinical suspicion of actinic granuloma and excluded other possibilities. Our patient was commenced on acitretin 25 mg/day and showed a remarkable improvement within a year; the lesions stopped spreading and almost disappeared.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689220     DOI: 10.1111/j.1365-4632.2005.02043.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  A Retrospective Study of 105 Patients with Elastolytic Giant Cell Granuloma and a Proposal for a New Clinical Classification.

Authors:  Yue-Tong Qian; Jia-Wei Liu; Wei Liu; Tian Chen; Yan Tan; Dong-Lai Ma
Journal:  Acta Derm Venereol       Date:  2022-03-28       Impact factor: 3.875

2.  Actinic granuloma.

Authors:  Reza Yaghoob; Nastaran Ranjbari; Amir Feily
Journal:  Dermatol Pract Concept       Date:  2014-07-31

3.  O'Brien Actinic Granuloma: A Case Report and Brief Review of Literature.

Authors:  Inês D Coutinho; Leonor I C Ramos; Maria M Brites; Oscar Tellechea
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.